New obesity drug put to the test: will it interfere with cholesterol meds?
NCT ID NCT06982131
First seen Nov 01, 2025 · Last updated Jun 18, 2026 · Updated 36 times
Summary
This early-stage study is testing an experimental oral drug called RO7795081 in 40 healthy overweight or obese adults. The main goals are to check the drug's safety and see how it affects two common cholesterol-lowering statins (pitavastatin and rosuvastatin). Participants will receive multiple doses of the drug or a placebo, and their blood levels and health markers will be closely monitored.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESITY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
ICON Plc (LPRA) - Netherlands
RECRUITINGGroningen, 9728 NZ, Netherlands
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.